TScan Therapeutics

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,

The American Society of Clinical Oncology annual meeting often is followed by several follow-on public offerings (FOPOs) by small- to mid-sized public biotech companies reporting positive data at the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical

Takeda Pharmaceutical Co. Ltd. unveiled its third gene therapy collaboration in less than two months on 12 October, this time teaming with Poseida Therapeutics, Inc. on a research, development and